Cutler Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Cutler Group’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,000	Closed	-$1K	–	4420
2023 Q1	$1K	Hold	1,000	–	–	﹤0.01%	3658
2022 Q4	$0	Hold	1,000	–	–	﹤0.01%	5545
2022 Q3	$1K	Hold	1,000	–	–	﹤0.01%	4794
2022 Q2	$2K	Hold	1,000	–	–	﹤0.01%	4441
2022 Q1	$2K	Hold	1,000	–	–	﹤0.01%	4839
2021 Q4	$4K	Buy	+1,000	New	+$6.25K	﹤0.01%	4428
2021 Q3	–	Sell	-700	Closed	-$11K	–	6612
2021 Q2	$11K	Buy	700 +100	+17%	+$2.02K	﹤0.01%	3857
2021 Q1	$13K	Sell	600 -1,000	-63%	-$27.3K	﹤0.01%	3607
2020 Q4	$49K	Buy	1,600 +1,300	+433%	+$32.9K	﹤0.01%	2035
2020 Q3	$6K	Sell	300 -800	-73%	-$14K	﹤0.01%	3428
2020 Q2	$16K	Buy	+1,100	New	+$12.7K	﹤0.01%	2564

Cutler Group's TCRR Position: Q2 2023 in Review

Cutler Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 1,000 shares — an estimated $1K sold.

Cutler Group first reported a position in TCRR in Q2 2020 and held it in 11 quarters. The position peaked at $49K in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Cutler Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cutler Group sold 1,000 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1K.
Cutler Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 11 quarters.
Cutler Group's TCR2 Therapeutics Inc. Common Stock position peaked at $49K in Q4 2020.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.